NCT06405061View on ClinicalTrials.gov

Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

August 1, 2027

Conditions
AdebrelimabHepatocellular Carcinoma
Interventions
DRUG

Adebrelimab

Adebrelimab: 1200 mg, IV, q3w

Trial Locations (4)

300308

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

Unknown

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

NOT_YET_RECRUITING

Third Central Hospital of Tianjin, Tianjin

NOT_YET_RECRUITING

Tianjin First Central Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER